Are pigeons going to take pathologists jobs? AI in oncology and therapeutics. Last session of first day #ASCOBT19 @asco @oncoalert Gregory Sorensen

When the democracy movement in HK actually involves senseless violence against the one who speaks against it, they put shame on the good name of democracy

Thanks to JCO for their extra hard work allowing this simultaneous publication to be possible

Two Journal of Clinical Oncology simultaneous pubs by Dr. Dennis Slamon and Tony Mok for #ASCO18 published on time! Link to papers ascopubs.org/jco/asco-2018-…

With ARCHER1050 we have proved that more potent EGFR inhibition may attain longer PFS and OS but at the price of higher toxicity. Tough choice!

Looking at the PDL1<1%/TC0 subgroup data of KN407, CM227 and IMpowere131, I seriously doubt if this group of pts with SCC should receive chemo+IO. TMB is the way to go for selecting Nivo/ipi in this group

Keynote 158 on SCLC surprised me a bit. RR in the PDL1positive subgroup (n=42) was 35.7% and result is durable. Looking forward to the phase 3

Need to see full data Monday from Tony Mok but IMO it is unlikely that daco can replace osi as top choice 1st line. Tox is signif worse, PFS is shorter in a study cohort w more favorable prognosis (no CNS mets). But 1st Egfr study w an OS benefit is an historic landmark! twitter.com/brendonstilesm…

Great job, Herbert twitter.com/herbloong/stat…

Great job, Herbert twitter.com/herbloong/stat…

Sunil Verma has provided us with an easy to read 2018 treatment algorithm for HER2 positive breast cancer at ASCO Post that even a lung cancer doc can understand. Thanks, Sunil.

Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 For adenocarcinoma of lung in non-smokers, I shall test for EGFR, ALK and ROS 1 first. Apart from these three there is a lack of first line data on other oncogenes in lung cancer. For others I may use NGS first I selective patients

My great honour in joining the ASCO board to serve the oncologist community twitter.com/hoosierdfh/sta…

Congratulations to all our scientists elected as fellows to The Royal Society, National Academy of Sciences, Academy of Medical Sciences and EMBO in the last couple of weeks! With so many to celebrate, we've run out of champagne 🥂👩‍🔬👨‍🔬

Since IPASS PFS became a well accepted endpoint. But when we compare TKI with TKI or TKI combo, should OS be the ultimate endpoint?

Delighted to meeting up so many friends in Twitter. AACR2018 is showcase of IO for first line NSCLC. ASCO2018 will be even better. We will have IO plus 3 phase III data on First line EGFR TKI

Tony Mok is happy to talk about lung Cancer and food